atropine has been researched along with fluoxetine in 29 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (fluoxetine) | Trials (fluoxetine) | Recent Studies (post-2010) (fluoxetine) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 10,100 | 1,663 | 3,263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.34) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Caliendo, G; Capasso, R; Ciano, A; Corvino, A; Di Vaio, P; Fiorino, F; Frecentese, F; Izzo, AA; Kędzierska, E; Kotlińska, JH; Magli, E; Massarelli, P; Orzelska-Gòrka, J; Perissutti, E; Rossi, I; Saccone, I; Santagada, V; Severino, B | 1 |
| Clemens, JA; Fuller, RW; Snoddy, HD | 1 |
| Allen, JM; Fairweather, I; Halton, DW; McKay, DM | 1 |
| Adler-Graschinsky, E; Butta, NV; Elgoyhen, AB | 1 |
| Camarasa, J; Camins, A; Canudas, AM; Escubedo, E; Pallàs, M; Pubill, D; Sureda, FX | 1 |
| Hodgson, WC; Ramasamy, S; Ventura, S | 1 |
| Brink, CB; de Kock, SE; Harvey, BH; Stein, DJ; Viljoen, SL | 1 |
| James, AN; Parkman, HP; Ryan, JP | 1 |
| Anjaneyulu, M; Chopra, K | 1 |
| Brink, CB; Clapton, JD; Eagar, BE; Harvey, BH | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N | 1 |
| Friedman, A; Heinemann, U; Melamed-Book, N; Ofek, K; Schoknecht, K; Soreq, H | 1 |
| Khin, PP; Sohn, UD; Zaw, TS | 1 |
| Mizutani, H; Sakakibara, F; Sasaki, E | 1 |
| Chen, B; Chu, C; Fang, L; Lin, T; Tong, S; Xu, P; You, H | 1 |
2 review(s) available for atropine and fluoxetine
| Article | Year |
|---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
27 other study(ies) available for atropine and fluoxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
New 5-HT
Topics: Animals; Binding Sites; Biological Assay; Ileum; Ligands; Maze Learning; Molecular Structure; Picolines; Protein Binding; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin Receptor Agonists | 2017 |
The effect of quipazine, a serotonin receptor agonist, on serum corticosterone concentration in rats.
Topics: 5-Hydroxytryptophan; 5,7-Dihydroxytryptamine; Animals; Atropine; Corticosterone; Dose-Response Relationship, Drug; Fluoxetine; Male; Metergoline; Quinolines; Quipazine; Rats; Serotonin Antagonists | 1978 |
The effects of cholinergic and serotoninergic drugs on motility in vitro of Haplometra cylindracea (Trematoda: Digenea).
Topics: Acetylcholine; Animals; Atropine; Carbachol; Fluoxetine; Methysergide; Movement; Nicotine; Parasympathomimetics; Physostigmine; Rana temporaria; Reserpine; Serotonin; Serotonin Antagonists; Trematoda; Tubocurarine | 1989 |
Serotonin uptake inhibitors and the prejunctional effects of serotonin on peripheral sympathetic nerves.
Topics: Animals; Atropine; Biological Transport, Active; Cats; Citalopram; Fluoxetine; Guinea Pigs; Heart Atria; Muscle Contraction; Myocardial Contraction; Nictitating Membrane; Norepinephrine; Peripheral Nerves; Propylamines; Serotonin; Serotonin Antagonists | 1986 |
Assessment of the adrenergic effects of orphenadrine in rat vas deferens.
Topics: Adrenergic Agents; Animals; Atropine; Binding, Competitive; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Epididymis; Fluoxetine; In Vitro Techniques; Ligands; Male; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Norepinephrine; Orphenadrine; Phencyclidine; Prazosin; Rats; Rats, Sprague-Dawley; Vas Deferens | 1999 |
Protein kinase C and the sub-sensitivity and sub-reactivity of the diabetic rat prostate gland to noradrenaline.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Fluoxetine; Immunohistochemistry; Indoles; Male; Maleimides; Methoxamine; Muscarinic Antagonists; Naphthalenes; Norepinephrine; Prazosin; Propranolol; Prostate; Protein Kinase C; Rats; Rats, Wistar | 2002 |
Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells.
Topics: Adrenergic Uptake Inhibitors; Androstadienes; Atropine; Cell Line, Tumor; Enzyme Inhibitors; Estrenes; Fluoxetine; Humans; Imipramine; Inositol; Muscarinic Antagonists; Neuroblastoma; Phosphatidylinositols; Phosphodiesterase Inhibitors; Pyrrolidinones; Receptor, Serotonin, 5-HT2A; Receptors, Muscarinic; Selective Serotonin Reuptake Inhibitors; Tritium; Wortmannin | 2004 |
Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility.
Topics: Adrenergic alpha-Antagonists; Animals; Atropine; Drug Interactions; Fluoxetine; Gastric Fundus; Guinea Pigs; In Vitro Techniques; Indoles; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Phentolamine; Pylorus; Receptors, Neurotransmitter; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stomach; Sulfonamides; Tetrodotoxin | 2005 |
Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fluoxetine; Male; Mice; Muscarinic Antagonists; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Receptors, Muscarinic; Receptors, Opioid; Secologanin Tryptamine Alkaloids; Serotonin Antagonists | 2006 |
Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.
Topics: Animals; Antidepressive Agents; Atropine; Brain; Cell Line, Tumor; Fluoxetine; Humans; Male; Motor Activity; Muscarinic Antagonists; Neurons; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic; Receptors, Muscarinic; Signal Transduction; Sildenafil Citrate; Sulfones | 2008 |
Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Atropine; Behavior, Animal; Carbolines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Swimming; Tadalafil | 2010 |
Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling.
Topics: Acetylcholinesterase; Animals; Arterioles; Atropine; Calcium; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; HSP90 Heat-Shock Proteins; Male; Mecamylamine; Methysergide; Muscarinic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Reperfusion; Selective Serotonin Reuptake Inhibitors; Serotonin; Signal Transduction; Stroke; Vasodilation | 2012 |
Signal Transduction Underlying the Inhibitory Mechanism of Fluoxetine on Electrical Field Stimulation Response in Rat Ileal Smooth Muscle.
Topics: 4-Aminopyridine; Amides; Animals; Atropine; Azepines; Benzophenanthridines; Bicuculline; Calcimycin; Drug Interactions; Electric Stimulation; Estrenes; Fluoxetine; Glyburide; Ileum; In Vitro Techniques; Indoles; Male; Muscle Contraction; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Ondansetron; Pyridines; Pyrrolidinones; Rats; Signal Transduction; Sulfonamides; Tetraethylammonium | 2017 |
TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder.
Topics: Adrenergic beta-3 Receptor Antagonists; Animals; Atropine; Carbachol; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Muscle Contraction; Muscle, Smooth; Rats; Receptors, Muscarinic; Urinary Bladder; Urinary Bladder, Overactive | 2020 |
Enantioseparation of five racemic N-alkyl drugs by reverse phase HPLC using sulfobutylether-β-cyclodextrin as a chiral mobile phase additive.
Topics: Atropine; beta-Cyclodextrins; Chromatography, High Pressure Liquid; Fluoxetine; Indicators and Reagents; Labetalol; Stereoisomerism; Venlafaxine Hydrochloride | 2022 |